In the first segment of this one-on-one interview series, Peter Salgo, MD, and Bryan Loy, MD, of Humana discuss the most influential recent innovations in cancer care.
Dr Loy comments that in addition to the targeted tests and therapies that continue to emerge, he finds remarkable the willingness of key stakeholders to collaborate and discuss the utilization of newer technologies, their costs, and the overall patient experience.
Dr Loy explains that understanding the role that genetics plays in cancer is important, and being able to comprehend the data and engage in dialogues regarding how to utilize emerging therapies can help all stakeholders in medical oncology deliver better quality care.
Because health literacy continues to be a real issue for patients, patients must be presented with information on these emerging treatment options in an understandable form. Additionally, everyone involved in patient care, from caregivers to those involved in reimbursement, should be accountable for sharing information with patients, suggests Dr Loy.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More